Long-Term Debt: Harpoon Tx (HARP)

Harpoon Therapeutics (HARP) relies on the international humanitarian status of its research and the support of US pharma behemoths. The development of universal platforms allows for the replication of tumor-fighting methods without additional costs, a fact reflected in the price history on the GURU.Markets chart at the level of 0.07. However, the high probability of clinical trial failure and the need for capital create significant uncertainties.

A fundamental valuation of Harpoon Therapeutics (HARP) requires an analysis of its capital structure stability. This metric measures the aggregate of credit obligations with maturities exceeding one year, determining the debt load on the balance sheet. By analyzing the company's long-term debt, an investor can track the dynamics of borrowed funds. This is critical for a biotech firm, as borrowings may fund the development of the TriTAC platform. A reduction in debt alongside the growth of intellectual property confirms the effectiveness of the licensing model.